Skip to main content
. 2011 Jun 14;19(9):1737–1746. doi: 10.1038/mt.2011.113

Figure 4.

Figure 4

Metronomic administration of low-dose cyclophosphamide (CP) in combination with oncolytic adenoviruses promotes a Th1 immune response profile. Total number of T cell was analyzed in (a) patients treated with oncolytic adenovirus only and (b) patients treated with oral CP together with the virus. (c) Cytokines profile was analyzed in patients treated with CP per os and adenovirus before and after the treatment. i.v., intravenous.